C² PHARMA and ANKLAM EXTRAKT^® announce R&D collaboration to develop cannabidiol-based compounds

• C² PHARMA is implementing its cannabis strategy by collaborating with ANKLAM EXTRAKT^®, a European-based manufacturer of botanical extracts with full GMP accreditations from the German authorities.
• The collaboration will provide pharmaceutical companies with a reliable supply of cannabis compounds with full regulatory support.

Luxembourg and Anklam, October 5, 2018 – C² PHARMA (Hall 6, Booth 6F40) and ANKLAM EXTRAKT^® (Hall 5, Booth 5G60) are announcing at CPhI 2018 in Madrid their R&D collaboration to develop GMP-compliant manufacture of cannabidiol CBD-based compounds. The collaboration between two leading companies in their respective fields covers various botanicals extracted from cannabis for pharmaceutical use. The new R&D program announced in the first phase include: 

• Cannabidiol (CBD) as an API
• Cannabis oil
• Cannabis extract

This collaboration supports C² PHARMA’s major initiative, announced on October 2, 2018, to bring a reliable source of naturally extracted GMP-compliant Cannabidiol (CBD) to the pharma industry. The initiative will leverage C² PHARMA’s established Good Agricultural Practices (GAP) process, analytical know-how at its affiliate ASM Research Chemicals (www.asm-research-chemicals.com) and logistics know-how at its affiliate Logistics4pharma (www.logistics4pharma.com).

It also supports ANKLAM EXTRAKT^® ’s strategy to continue its expansion in the pharmaceutical sector and offer a broad range of GMP-compliant botanical extracts to the industry.

Initial samples are expected to be available in the first quarter of 2019.

“Our collaboration with ANKLAM EXTRAKT^® allows two expert companies to work together to deliver what the pharma industry needs: a reliable source of cannabis-derived compounds and APIs for the long term,” said Andrew Badrot, CEO of C² PHARMA said. “Drawing on the complementary expertise of our affiliates, we jointly cover the entire cannabis supply chain, from GAP cultivation, to GMP manufacturing, analytics, transportation and warehousing. It is a value proposition that is hard to beat.”

“We are delighted to work with C² PHARMA and to be able to contribute to their vision to build a reliable source of CBD-based compounds. They have the market access, regulatory knowledge and the energy to push this complex project through,” said Claudia Pühn, Managing Director of ANKLAM EXTRAKT^®. “Combined with ANKLAM EXTRAKT^® ’s manufacturing capabilities, compliance with German regulations and expertise in botanical extracts, this collaboration is bound to be successful.”

For more information visit: www.c2pharma.com
 

About C² PHARMA
C² PHARMA (formerly known as Centroflora CMS) is a Luxembourg-based pharmaceutical group established in 2014 which manufactures and distributes its Active Pharmaceutical Ingredients (“APls”) and complex chemical compounds from phytochemical and chemical origins.
The current API product portfolio includes atropine, digoxin, homatropine, pilocarpine, N-butylbromide scopolamine / hyoscine (SNBB), and reaches more than 100 pharmaceutical companies across the United States, Western and Eastern Europe, South America, Asia, Middle-East & Africa.
 

About ANKLAM EXTRAKT^®
ANKLAM EXTRAKT^® represents leading expertise in the development and production of high quality plant extracts. All our employees use their specific expertise, their experience and the latest cutting-edge technology to ensure that our products are of outstanding quality. We support you with our comprehensive service – from the natural raw materials through to the finished product.

Contact:
Marcelo Reinhardt
info@c2pharma.com
tel: +352 28 26 11 00